Sponsored by:

Molecular Imaging

Quantum BioPharma reports early results from MS PET imaging study
By AuntMinnie.com staff writers
If validated, the imaging approach could be used to measure how therapies affect myelin preservation and regeneration.
May 18, 2026
Pet Brain
ISMRM: PET/MRI-guided treatment reduces low back pain
By Will Morton
This study is the first to acquire follow-up FDG-PET/MRI scans after treatment to assess the correlation between clinical outcome and FDG uptake.
May 15, 2026
A 70-year-old female patient with chronic low back pain. History of radicular syndrome which led to targeted nerve block with positive effect. However, lower back pain persisted. FDG-PET/MRI showed increased FDG uptake in a disc herniation at L5-S1 (SUVmax 1.6) convincing the treating physician to proceed to discectomy. After discectomy, the patient is now mostly pain free.
SNMMI highlights new radiopharmaceutical therapy
By AuntMinnie.com staff writers
Mice bearing PDAC xenografts received lutetium-177 (Lu-177) AKIR001, a radiopharmaceutical that targets CD44v6.
May 13, 2026
Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.
Bayer issues positive report for cardiac amyloidosis radiotracer
By AuntMinnie.com staff writers
I-124 evuzamitide met its primary endpoints, according to Bayer.
May 7, 2026
Bayer w6 My4 Ipr De
PSMA-PET linked to higher use of systemic therapies
By Will Morton
ARPI therapy was initiated in 15.6% of PSMA-PET patients versus 7.7% of bone scan patients.
May 7, 2026
Psma Pet
Eden Radioisotopes files NRC permit for isotope production complex
By AuntMinnie.com staff writers
The company said the facility is designed to produce up to 50% of global demand for molybdenum-99 (Mo-99).
May 6, 2026
Isotopes
Chinese scientists develop wearable brain PET system
By Will Morton
The system could offer new opportunities for brain PET imaging beyond the constraints of conventional static systems.
May 1, 2026
(A) System comprises detectors and silicon photomultipliers with custom Hoffman brain phantom. (B) Seated-position scanning. (C) Backpack system permitting data collection in ambulatory states. (D) Workstation scenario demonstrating natural seated use.
NET tracers first widened, then closed imaging access gap
By Will Morton
Ga-68 DOTATATE/DOTATOC captured 33.8% market share in its 2017 debut and reached 90.9% by 2020.
April 30, 2026
Adobe Stock 107601498
Serac highlights study on 99mTc-maraciclatide for endometriosis care
By AuntMinnie.com staff writers
Serac Healthcare is highlighting success from a study that evaluated the company's gamma-emitting radiotracer, 99mTc-maraciclatide.
April 30, 2026
Endometriosis 3 D Illustration 400
Lu-177 PSMA-SPECT/CT predicts survival in mCRPC
By Will Morton
Lu-177 PSMA-617 SPECT/CT total tumor volume complete response at six weeks associated with overall survival.
April 29, 2026
Quantification of total tumor volume (TTV) at lutetium-177 prostate-specific membrane antigen (PSMA)–617 SPECT/CT shows heterogeneous TTV responses between dose 1 (Cycle #1) and dose 2 (Cycle #2) in participants with metastatic castration-resistant prostate cancer. Posttherapy coronal attenuation-corrected noncontrast SPECT/CT maximum intensity projection images demonstrate (A) near-complete response in a 76-year-old man, (B) complete response in an 83-year-old man, (C) partial TTV reduction (not complete response) in a 69-year-old man, and (D) TTV increase (i.e. progressive disease) in a 74-year-old man. Blue-shaded regions represent semiautomatically segmented PSMA-avid tumor volume, with associated TTV values given at the bottom of each panel. The gradient bar shows standardized uptake value (SUV) from 0 to 5.
PET improves treatment planning for pituitary tumors
By Will Morton
Ga-68 DOTATATE PET altered radiation treatment volumes by nearly 20% compared with MRI alone.
April 28, 2026
A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).
PharmaLogic opens PET radiopharmaceutical facility in Atlanta
By AuntMinnie.com staff writers
PharmaLogic Holdings has opened a PET radiopharmaceutical manufacturing facility in Atlanta.
April 28, 2026
Georgia Atlanta Map Pin
Page 1 of 626
Next Page